Effect of fentanyl buccal tablet on pain-related anxiety: A 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain

Journal of Opioid Management

Volumn 7, Issue 4, 2011, Pages 297-308

  Webster, Lynn R ^a   Messina, John ^b   Xie, Fang ^b   Nalamachu, Srinivas ^c  

^a Salt Lake Regional Medical Center   (United States)

^b CEPHALON INC   (United States)

^c Mid America Physiatrists   (United States)

Author keywords

Anxiety; Breakthrough pain; Chronic pain; Fentanyl buccal tablet

Indexed keywords

FENTANYL; OPIATE;

ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CHRONIC PAIN; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PAIN ASSESSMENT; PATIENT ASSESSMENT; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, BUCCAL; ADULT; ANALGESICS, OPIOID; ANXIETY; CHRONIC DISEASE; DRUG TOLERANCE; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; QUESTIONNAIRES; TABLETS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 80052741660     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0071     Document Type: Article

References (35)

1. Chou R, Clark E, Helfand M: Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage. 2003; 26(5): 1026-1048.
2. Manchikanti L, Singh V, Datta S, et al.: Comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician. 2009; 12(4): E35-E70.
3. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.
4. Portenoy RK, Bennett DS, Rauck R, et al.: Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006; 7(8): 583-591. (Pubitemid 44137488)
5. Portenoy RK, Hagen NA: Breakthrough pain: Definition, prevalence and characteristics. Pain. 1990; 41(3): 273-281. (Pubitemid 20187930)
6. Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain. 1999; 81(1-2): 129-134. (Pubitemid 29199908)
7. Svendsen KB, Andersen S, Arnason S, et al.: Breakthrough pain in malignant and non-malignant diseases: A review of prevalence, characteristics and mechanisms. Eur J Pain. 2005; 9(2): 195-206. (Pubitemid 40311842)
8. Zeppetella G, O'Doherty CA, Collins S: Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000; 20(2): 87-92.
9. Bennett DS, Simon S, Brennan M, et al.: Prevalence and characteristics of breakthrough pain in patients receiving opioids for chronic back pain in pain specialty clinics. J Opioid Manag. 2007; 3(2): 101-106. (Pubitemid 46760150)
10. Taylor DR, Webster LR, Chun SY, et al.: Impact of breakthrough pain on quality of life in patients with chronic, non-cancer pain: Patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med. 2007; 8(3): 281-288. (Pubitemid 46443468)
11. Caraceni A, Martini C, Zecca E, et al.: Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004; 18(3): 177-183.
12. McCracken LM, Zayfert C, Gross RT: The Pain Anxiety Symptoms Scale: Development and validation of a scale to measure fear of pain. Pain. 1992; 50(1): 67-73.
13. Burns JW, Mullen JT, Higdon LJ, et al.: Validity of the pain anxiety symptoms scale (PASS): Prediction of physical capacity variables. Pain. 2000; 84(2-3): 247-252. (Pubitemid 30074226)
14. Mercadante S, Radbruch L, Caraceni A, et al.: Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002; 94(3): 832-839. (Pubitemid 34132314)
15. Hwang SS, Chang VT, Kasimis B: Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003; 101(1-2): 55-64. (Pubitemid 36044654)
16. Bennett D, Burton AW, Fishman S, et al.: Consensus panel recommendations for the assessment and management of breakthrough pain, Part 2: Management. P&T. 2005; 30(6): 354-361.
17. Vissers D, Stam W, Nolte T, et al.: Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010; 26(5): 1037-1045.
18. Darwish M, Kirby M, Robertson P Jr, et al.: Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol. 2007; 47(3): 343-350. (Pubitemid 46294716)
19. Darwish M, Kirby M, Robertson P Jr, et al.: Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J Clin Pharmacol. 2007; 47(1): 56-63. (Pubitemid 44973998)
20. Durfee S, Messina J, Khankari R: Fentanyl effervescent buccal tablets: Enhanced buccal absorption. Am J Drug Deliv. 2006; 4(1): 1-5.
21. Simpson DM, Messina J, Xie F, et al.: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007; 29(4): 588-601.
22. Slatkin NE, Xie F, Messina J, et al.: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007; 5(7): 327-334. (Pubitemid 350055013)
23. Portenoy RK, Taylor D, Messina J, et al.: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006; 22(9): 805-811. (Pubitemid 44627444)
24. Portenoy RK, Messina J, Xie F, et al.: Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study. Curr Med Res Opin. 2007; 23(1): 223-233. (Pubitemid 46191684)
25. International Conference on Harmonisation Working Group: ICH harmonised tripartite guideline: Guideline for good clinical practice E6 (R1). Paper presented at the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Washington, DC, June 10, 1996.
26. Beck AT, Ward CH, Mendelson M, et al.: An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4: 561-571.
27. Kerns RD, Turk DC, Rudy TE: The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain. 1985; 23(4): 345-356. (Pubitemid 16212847)
28. Crombez G, Vlaeyen JW, Heuts PH, et al.: Pain-related fear is more disabling than pain itself: Evidence on the role of pain-related fear in chronic back pain disability. Pain. 1999; 80(1-2): 329-339. (Pubitemid 29151718)
29. McCracken LM, Gross RT: The role of pain-related anxiety reduction in the outcome of multidisciplinary treatment for chronic low back pain: Preliminary results. J Occup Rehabil. 1998; 8(3): 179-189. (Pubitemid 28462735)
30. Spertus IL, Burns J, Glenn B, et al.: Gender differences in associations between trauma history and adjustment among chronic pain patients. Pain. 1999; 82(1): 97-102. (Pubitemid 29287091)
31. Wasan AD, Davar G, Jamison R: The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain. 2005; 117(3): 450-461. (Pubitemid 41383540)
32. Zvolensky MJ, Goodie JL, McNeil DW, et al.: Anxiety sensitivity in the prediction of pain-related fear and anxiety in a heterogeneous chronic pain population. Behav Res Ther. 2001; 39(6): 683-696. (Pubitemid 32280208)
33. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23(2): 129-138.
34. Keller S, Bann CM, Dodd SL, et al.: Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004; 20(5): 309-318. (Pubitemid 39108843)
35. Fine PG, Messina J, Xie F, et al.: Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: An 18-month study. J Pain Symptom Manage. 2010; 40(5): 747-760.